United States Contraceptive Devices Market to Reach US$ 5.81 Billion by 2033 | Top Companies - CooperSurgical, Inc., Pregna International Limited, Reckitt Benckiser Group | Exclusive report by DataM intelligence

Leander, Texas and Tokyo, Japan - Jan.19.2026
As per DataM intelligence research report "The Global Contraceptive Devices Market reached US$10.98 billion in 2024 and is expected to reach US$19.37 billion by 2033, growing at a CAGR of 6.6% during the forecast period of 2025-2033."

The contraceptive devices market is expanding with innovations in user-friendly, long-acting, and digital-enabled solutions. Advanced materials, smart delivery systems, and precision contraceptive technologies enhance safety and compliance. Increasing awareness, family planning initiatives, and healthcare access are fueling global market growth.

Download your exclusive sample report today: (corporate email gets priority access):
https://www.datamintelligence.com/download-sample/contraceptive-devices-market?prasad

Contraceptive Devices Market: Competitive Intelligence
CooperSurgical, Inc., Pregna International Limited, Reckitt Benckiser Group, Veru Inc., Bayer AG, Abbvie Inc

In the Contraceptive Devices Market, CooperSurgical, Inc., Pregna International Limited, Reckitt Benckiser Group, Veru Inc., Bayer AG, and AbbVie Inc collectively strengthen a critical segment of reproductive healthcare by expanding the availability, choice, and quality of contraception technologies for diverse populations. These companies supply a range of device‐based contraceptive options-including intrauterine systems (IUS), intrauterine devices (IUDs), barriers, and other women's health products that support family planning, reduce unintended pregnancies, and align with broader public health goals. Their portfolios integrate clinically validated designs, safety‐focused materials, and user‐oriented features that help providers and consumers balance efficacy with tolerability and convenience. Through investments in manufacturing excellence, regulatory compliance, and global distribution networks, they improve access across developed and emerging regions. Together, they reinforce the Contraceptive Devices Market as an essential component of reproductive health infrastructure, addressing evolving patient needs while supporting healthcare system objectives around preventive care and women's autonomy.

Individually and in synergy, these organizations' capabilities enhance innovation and competitive differentiation within the Contraceptive Devices Market by blending product diversity, scientific rigor, and customer support. CooperSurgical, Inc. brings specialized reproductive health portfolios and clinician engagement that help integrate advanced device options into standard care pathways. Pregna International Limited strengthens market breadth with cost‐effective, quality‐assured contraception devices suited to diverse healthcare settings, especially in emerging markets. Reckitt Benckiser Group leverages strong consumer health branding and accessibility to broaden adoption of barrier and over‐the‐counter contraceptive solutions. Veru Inc.'s focus on next‐generation women's health technologies adds depth to the market's innovation pipeline. Bayer AG contributes extensive research, development, and global commercialization capacity that supports both long‐acting and short‐acting contraceptive devices, while AbbVie Inc. enhances the landscape with targeted women's health initiatives and integrated care solutions. Together, these companies help drive the Contraceptive Devices Market forward by delivering a mix of trusted, accessible, and technologically advanced options that empower individuals and healthcare providers to make informed reproductive health choices.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/contraceptive-devices-market?prasad

United States: Recent Industry Developments

✅ In January 2026, Bayer Healthcare deployed automated contraceptive device assembly lines with AI-assisted monitoring and robotics integration to ensure high precision, quality, and safety for IUDs and implants.

✅ In November 2025, Teva Pharmaceuticals invested $40 million to scale robotics-assisted contraceptive device manufacturing with AI quality analytics to optimize production consistency and regulatory compliance.

✅ In August 2025, CooperSurgical implemented automated packaging and inspection systems for contraceptive devices, combining AI monitoring and robotic handling to reduce errors and improve throughput.

✅ In June 2025, Hologic deployed AI-monitored automated assembly platforms for contraceptive devices to standardize production and enhance safety.

Japan: Recent Industry Developments

✅ In January 2026, Olympus Corporation deployed AI-assisted robotics for contraceptive device assembly, supported by $25 million investment, integrating real-time monitoring to enhance accuracy, safety, and consistency.

✅ In October 2025, Terumo Corporation implemented robotics-assisted production and inspection platforms for contraceptive devices with AI quality monitoring to optimize reliability.

✅ In July 2025, Fuji Medical Instruments introduced automated contraceptive device assembly with AI-assisted monitoring and robotic handling to improve efficiency and precision.

✅ In April 2025, Nipro Corporation deployed AI-monitored automated workflows for contraceptive device manufacturing, enhancing production quality and consistency.

Segment Covered in the Contraceptive Devices Market:
By Product Type
The market is segmented into condoms 35%, intrauterine devices (IUDs) 30%, sub-dermal implants 15%, vaginal rings 8%, diaphragms & cervical caps 7%, and sponges 5%, with condoms dominating due to affordability, ease of access, and dual protection against pregnancy and sexually transmitted infections. IUDs and sub-dermal implants show strong growth due to long-acting and reversible contraception benefits. Vaginal rings and barrier devices cater to specific user preferences. Rising awareness and family planning initiatives support market growth.

By Technology
Technologies include hormonal contraceptives 60% and barrier contraceptives 40%, with hormonal methods leading due to higher effectiveness and long-term pregnancy prevention. Barrier contraceptives remain widely used for their non-hormonal nature and STI protection. Continuous product innovation and improved safety profiles drive adoption across both segments.

By Gender
By gender, the market is segmented into female 70% and male 30%, with female contraceptives dominating due to broader product availability and long-term options such as IUDs and implants. Male contraceptives are primarily limited to condoms, though ongoing R&D is expected to diversify offerings. Changing social attitudes and shared responsibility trends support gradual male segment growth.

By Distribution Channel
Distribution channels include retail pharmacies 40%, hospital pharmacies 25%, online channels 25%, and others 10%, with retail pharmacies dominating due to accessibility and consumer trust. Online channels are rapidly growing with discreet purchasing and expanding e-commerce penetration. Hospital pharmacies are key for long-acting contraceptives. Improved supply chains and digital health platforms enhance distribution efficiency.

Buy Now & Unlock 360° Market Intelligence:
https://www.datamintelligence.com/buy-now-page?report=contraceptive-devices-market

Regional Analysis
Asia Pacific - 35% Share
Asia Pacific leads with 35% share driven by large population base, government family planning programs, and rising awareness in China, India, and Southeast Asia. Condoms and IUDs dominate product demand. Retail and hospital pharmacies are primary channels. Public health initiatives and affordability drive market growth.

North America - 25% Share
North America holds 25% share supported by high adoption of hormonal contraceptives and long-acting reversible devices in the U.S. and Canada. IUDs, implants, and vaginal rings are widely used. Retail pharmacies and online channels dominate distribution. Favorable reimbursement policies and sexual health awareness support growth.

Europe - 20% Share
Europe accounts for 20% share driven by strong sexual health education and access to modern contraceptives in Germany, France, and the UK. Hormonal contraceptives dominate technology adoption. Hospital and retail pharmacies are key channels. Government-supported reproductive health services drive steady demand.

Latin America - 10% Share
Latin America records 10% share with growing adoption in Brazil, Mexico, and Argentina. Condoms and hormonal contraceptives are widely used. Retail pharmacies dominate distribution. Public health campaigns and urbanization support market expansion.

Middle East & Africa - 10% Share
Middle East & Africa holds 10% share with increasing awareness and gradual adoption in South Africa, UAE, and Saudi Arabia. Condoms and barrier contraceptives dominate due to cultural preferences. Retail pharmacies are primary distribution channels. Government and NGO initiatives drive market penetration.

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?prasad

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.